Iovance Biotherapeutics, Inc. (IOVA)
USD 3.26
(2.04%)
USD 3.26
(2.04%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1.18 Million | - | - | - | - | - |
| Cost of Revenue | 10.75 Million | 21.13 Million | 13.98 Million | 8.71 Million | 8.12 Million | 956 Thousand |
| Gross Profit | -9.56 Million | -21.13 Million | -13.98 Million | -8.71 Million | -8.12 Million | -956 Thousand |
| Operating Expenses | 450.99 Million | 398.87 Million | 342.7 Million | 261.93 Million | 206.87 Million | 128.25 Million |
| Selling, General and Administrative Expenses | 106.91 Million | 104.09 Million | 83.66 Million | 60.21 Million | 40.84 Million | 28.43 Million |
| Research and Development Expenses | 344.07 Million | 294.78 Million | 259.03 Million | 201.72 Million | 166.02 Million | 99.82 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 461.74 Million | 398.87 Million | 342.7 Million | 261.93 Million | 206.87 Million | 128.25 Million |
| Operating Income | -460.55 Million | -398.87 Million | -342.7 Million | -261.93 Million | -206.87 Million | -128.25 Million |
| Interest Expense | - | 2.98 Million | - | - | - | - |
| Income Tax Expense | -3.47 Million | -5.97 Million | -14.43 Million | -2.35 Million | -10.48 Million | 4.67 Million |
| Earnings before Tax | -447.51 Million | -395.89 Million | -342.25 Million | -259.58 Million | -197.55 Million | -123.58 Million |
| Net Income | -444.03 Million | -389.92 Million | -327.82 Million | -257.22 Million | -187.07 Million | -123.58 Million |
| Earnings Per Share Basic | -1.89 | -2.45 | -2.14 | -1.86 | -1.50 | -1.27 |
| Earnings Per Share Diluted | -1.89 | -2.45 | -2.14 | -1.86 | -1.50 | -1.27 |
| Weighted Average Shares Outstanding | 235.13 Million | 159.25 Million | 153.4 Million | 138.3 Million | 124.33 Million | 97.27 Million |
| Weighted Average Shares Outstanding (Diluted) | 235.13 Million | 159.25 Million | 153.4 Million | 138.3 Million | 124.33 Million | 97.27 Million |
| Gross Margin | -8.05 | - | - | - | - | - |
| EBIT Margin | -359.49 | - | - | - | - | - |
| Profit Margin | -373.45 | - | - | - | - | - |
| EBITDA | -427.43 Million | -374.75 Million | -328.27 Million | -250.86 Million | -189.43 Million | -122.62 Million |
| Earnings Before Tax Margin | -387.35 | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 31.1 Million | 715 Thousand | 1.18 Million | 482 Thousand | 469 Thousand | 238 Thousand |
| Cost of Revenue | 36.74 Million | 12.53 Million | 33.12 Million | 14.07 Million | 4.34 Million | 2.05 Million |
| Gross Profit | -5.64 Million | -11.82 Million | -31.93 Million | -13.59 Million | -3.87 Million | -1.81 Million |
| Operating Expenses | 96.27 Million | 105.9 Million | 428.62 Million | 107.65 Million | 114.49 Million | 108.27 Million |
| Selling, General and Administrative Expenses | 34.19 Million | 26.11 Million | - | 20.18 Million | 26.96 Million | 21.92 Million |
| Research and Development Expenses | 62.08 Million | 79.78 Million | - | 87.47 Million | 87.52 Million | 86.34 Million |
| Other Expenses | - | - | - | 5.69 Million | - | - |
| Cost and Expenses | 133.02 Million | 118.43 Million | 461.74 Million | 121.73 Million | 118.83 Million | 110.32 Million |
| Operating Income | -101.91 Million | -117.72 Million | -460.55 Million | -121.25 Million | -118.36 Million | -110.08 Million |
| Interest Expense | - | - | - | 3.48 Million | - | - |
| Income Tax Expense | -1.45 Million | -1.4 Million | -3.47 Million | -1.75 Million | -1.24 Million | -477 Thousand |
| Earnings before Tax | -98.55 Million | -114.38 Million | -447.51 Million | -118.13 Million | -115 Million | -107 Million |
| Net Income | -97.1 Million | -112.97 Million | -444.03 Million | -116.37 Million | -113.76 Million | -106.52 Million |
| Earnings Per Share Basic | -0.34 | -0.42 | - | -0.45 | -0.46 | -0.47 |
| Earnings Per Share Diluted | -0.34 | -0.42 | - | -0.45 | -0.46 | -0.47 |
| Weighted Average Shares Outstanding | 284.81 Million | 266.22 Million | 235.13 Million | 255.95 Million | 245.81 Million | 224.48 Million |
| Weighted Average Shares Outstanding (Diluted) | 284.81 Million | 266.22 Million | 235.13 Million | 255.95 Million | 245.81 Million | 224.48 Million |
| Gross Margin | -0.18 | -16.53 | -26.86 | -28.21 | -8.25 | -7.61 |
| EBIT Margin | -2.93 | -150.79 | - | -231.41 | -252.37 | -462.55 |
| Profit Margin | -3.12 | -158.01 | -373.45 | -241.45 | -242.56 | -447.60 |
| EBITDA | -91.05 Million | -107.81 Million | - | -111.54 Million | -118.36 Million | -110.08 Million |
| Earnings Before Tax Margin | -3.28 | -164.65 | -387.35 | -251.57 | -252.37 | -462.55 |
000820
TXAR
GLNLF
OMMSF
SU
YMM